A multidisciplinary Delphi consensus on budesonide aqueous nasal spray in managing upper respiratory diseases

Giorgio Ciprandi; Ignazio La Mantia; Attilio Varricchio; Study Group on Topical Nasal Therapy

doi:10.5826/mrm.2025.1015

A multidisciplinary Delphi consensus on budesonide aqueous nasal spray in managing upper respiratory diseases

Authors

Giorgio Ciprandi Casa di Cura Villa Montallegro http://orcid.org/0000-0001-7016-8421
Ignazio La Mantia
Attilio Varricchio
Study Group on Topical Nasal Therapy

DOI: https://doi.org/10.5826/mrm.2025.1015

Keywords:

budesonide, allergic rhinitis

Abstract

Allergic rhinitis (AR), non-allergic rhinitis (NAR), and chronic rhinosinusitis with nasal polyps (CRSwNP) share a type 2 inflammation. Thus, intranasal corticosteroids (INCS) are recommended for managing these diseases. In this regard, budesonide aqueous nasal spray (BANS) has been an effective and safe INCS available for decades. As a recent Delphi consensus and a survey explored the use of topical nasal therapy in practice, a panel of experts promoted a multidisciplinary Delphi consensus on BANS in daily practice. Forty-six Italian expert otorhinolaryngologists, allergologists, and pediatricians participated in the initiative. Twenty-one statements were voted on. There was a large agreement with all statements. Thus, this document proposed a valuable BANS use in managing patients with AR, NAR, or CRSwNP considering the relevant activity on dampening type 2 inflammation.
Moreover, the safety profile was considered good, also concerning the bioavailability issue. However, based on the severity of the disease, BANS use should be prescribed as cycles or for prolonged periods.
In conclusion, the present multidisciplinary Delphi consensus supported BANS use in upper airway type 2 diseases.

References

1. Ciprandi G. Recent advances in the practical management of allergic rhinitis. Recenti Prog Med 2024;115(4):1-10.

2. Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C, et al. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2017;72(11):1657-65.

3. Kopp EB, Agaronyan K, Licona-Limón I, Nish SA, Medzhitov R. Modes of type 2 immune response initiation. Immunity 2023;56(4):687-94.

4. Wang S, Liu X, Lin X, Lv X, Zhang H. Group 2 -Innate Lymphoid Cells in Allergic Rhinitis. J Inflamm Res 2024;17:8599-610.

5. Bernstein JA, Bernstein JS, Makol R, Ward S. Allergic rhinitis. A review. JAMA 2024;331(10):866-77.

6. Shah SA, Kobayashi M. Pathogenesis of chronic rhinosinusitis with nasal polyp and a prominent T2 endotype. Heliyon 2023;9(9):e19249.

7. Kato A. Immunopathology of chronic rhinosinusitis. -Allergol Int 2015;64(2):121-30.

8. Fowler J, Sowerby LJ. Using intranasal corticosteroids. CMAJ 2021;193(2):E47.

9. Sousa-Pinto B, Vieira RJ, Bognanni A, Gil-Mata S, -Ferreira-da-Silva R, Ferreira A, et al. Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis. Allergy 2025;80(1):94-105.

10. Warland A, Møller P, Lindqvist N. Budesonide - a new steroid for intranasal use. A double-blind clinical comparison between budesonide and placebo in patients with seasonal allergic rhinitis. Allergy 1981;36(6):425-8.

11. Ciprandi G. Budenoside aqueous nasal spray: an updated reappraisal in rhinitis management. Minerva Med 2024;115(2):203-213.

12. Ciprandi G. The updated role of budesonide in managing children and adolescents with allergic rhinitis. Minerva Pediatr (Torino) 2024;76(4):526-36.

13. Ciprandi G. Budesonide aqueous nasal spray: an updated review in managing chronic rhinosinusitis with nasal -polyps. Panminerva Med 2024;66(3):317-23.

14. Varricchio A, Presutti L, La Mantia I, Ciprandi G. Inter-societal Delphi Consensus on the topical nasal treatments in Italy. Multidiscip Respir Med 2024;19(1):991.

15. Varricchio A, Presutti L, La Mantia I, Varricchio An, Ciprandi G. Inter-societal Survey on the topical ytreatments in Italy. Multidiscip Respir Med 2024;19:993.

16. Torres MI, Gil-Mata S, Bognanni A, Ferreira-da-Silva R, Yepes-Nunez JJ, Lourenco-Silva N, et al. Intranasal Versus Oral Treatments for Allergic Rhinitis: A Systematic Review With Meta-Analysis. J Allergy Clin Immunol Pract 2024;12(12):3404-18.

17. Bousquet J, Schünemann HJ, Sousa-Pinto B, Zuberbier T, Togias A, Samolinski B, et al. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024). J Allergy Clin Immunol Pract 2024;12(10):2648-68.e2.

18. Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp -Allergy 2017;47(7):856-89.

19. Park DY, Lee YJ, Kim DK, Kim AW, Yang HJ, Kim DH, et al. KAAACI Allergic Rhinitis Guidelines: Part 2. Update in Non-pharmacological Management. -Allergy Asthma Immunol Res 2023;15(2):145-59.

20. Dykewicz MS, Wallace DV, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol 2020;146(4):721-67.

21. Wise SK, Damask C, Roland LT, Ebert C, Levy JM, Lin S, et al. International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol 2023;13(4):293-859.

22. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol 2007;21(1):70-9.

23. Thorsson L, Borgâ O, Edsbäcker S. Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. Br J Clin Pharmacol 1999;47(6):619-24.

24. Bachert C, Hicks A, Gane S, Peters AT, Gevaert P, Nash S, et al. The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol 2024;15:1356298.

25. Hellings PW, Lau S, Scadding GK, Bjermer L, Backer V, Chaker AM, et al. EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care. Front Allergy 2023;4:1236977.

26. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 2020;Suppl. 29:1-464.

27. Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology 2023;61(3):194-202.

28. Rollema C, van Roon EN, van Boven JFM, Hagedoorn P, Klemmeier T, Kocks JH, et al. Pharmacology, particle deposition and drug administration techniques of intranasal corticosteroids for treating allergic rhinitis. Clin Exp -Allergy 2022,52:1247-63.